MedTrace Logo

Herbal Tea in the Treatment of Type 2 Diabetes Mellitus

NCT03787563 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2018-12-26

No results posted yet for this study

Summary

Diabetes mellitus is a chronic disease caused by inherited and/or acquired deficiency in production of insulin by the pancreas, or by the ineffectiveness of the insulin produced. It has become a major healthcare problem in India. High-quality, low-cost solutions adapted to the local context are critical to addressing the current crisis in the management of diabetes. Herbal tea consists of tulsi, guava and stevia, which has glucose lowering properties.The aim of this trial is to study the effect of a herbal tea in the glycemic response in the early type 2 diabetes.

Conditions

Interventions

DRUG

Herbal Tea

All participants will be given the intervention in an infusion tea bag. Participant will be instructed to take one tea bag three times a day at before breakfast, lunch and dinner meals. At the time of randomization both active and placebo infusion bag will be provided.There will be one day of washout period after 2 days on treatment.

DRUG

Placebo Tea

Similar looking inert placebo tea.

Sponsors & Collaborators

  • Composite Interceptive Med-Science Laboratories Pvt Ltd

    collaborator UNKNOWN

  • Composite Interceptive Med Science

    lead INDUSTRY

Principal Investigators

  • HD Ramachandra Prabhu, MBBS, MD · Health India Hospital

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2019-01-15
Completion
2019-01-20

Countries

  • India

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03787563 on ClinicalTrials.gov